The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice

Joseph Zouein; Fady G. Haddad; Roland Eid; Hampig R. Kourie

doi:10.2217/imt-2021-0014

The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice

Joseph Zouein, Fady G. Haddad, Roland Eid, Hampig R. Kourie

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve cancer prognosis. However, longer follow-up has confirmed the possibility of acquired resistance to immune checkpoint inhibitors (ICIs) which can lead to late relapses. Chemotherapy can act as a priming therapy to increase a tumor's response to immunotherapy. We aim through this review to explain the mechanism behind ICI resistance and the value of chemotherapy in escaping this resistance. Finally, all US FDA approvals regarding the management of metastatic non-small-cell lung cancer using a combination of ICIs and chemotherapy are summarized.

Original language	English (US)
Pages (from-to)	155-167
Number of pages	13
Journal	Immunotherapy
Volume	14
Issue number	2
DOIs	https://doi.org/10.2217/imt-2021-0014
State	Published - Feb 2021
Externally published	Yes

Keywords

chemotherapy
combination therapy
hyperprogressive disease
immune checkpoint inhibitors
immunotherapy
microenvironment
NSCLC
tumor inflammation

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2021-0014

Cite this

@article{e6fe7290b27f47fe843d4c0a0774d48e,

title = "The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice",

abstract = "Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve cancer prognosis. However, longer follow-up has confirmed the possibility of acquired resistance to immune checkpoint inhibitors (ICIs) which can lead to late relapses. Chemotherapy can act as a priming therapy to increase a tumor's response to immunotherapy. We aim through this review to explain the mechanism behind ICI resistance and the value of chemotherapy in escaping this resistance. Finally, all US FDA approvals regarding the management of metastatic non-small-cell lung cancer using a combination of ICIs and chemotherapy are summarized.",

keywords = "chemotherapy, combination therapy, hyperprogressive disease, immune checkpoint inhibitors, immunotherapy, microenvironment, NSCLC, tumor inflammation",

author = "Joseph Zouein and Haddad, {Fady G.} and Roland Eid and Kourie, {Hampig R.}",

note = "Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.",

year = "2021",

month = feb,

doi = "10.2217/imt-2021-0014",

language = "English (US)",

volume = "14",

pages = "155--167",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer

T2 - the rational choice

AU - Zouein, Joseph

AU - Haddad, Fady G.

AU - Eid, Roland

AU - Kourie, Hampig R.

PY - 2021/2

Y1 - 2021/2

N2 - Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve cancer prognosis. However, longer follow-up has confirmed the possibility of acquired resistance to immune checkpoint inhibitors (ICIs) which can lead to late relapses. Chemotherapy can act as a priming therapy to increase a tumor's response to immunotherapy. We aim through this review to explain the mechanism behind ICI resistance and the value of chemotherapy in escaping this resistance. Finally, all US FDA approvals regarding the management of metastatic non-small-cell lung cancer using a combination of ICIs and chemotherapy are summarized.

AB - Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve cancer prognosis. However, longer follow-up has confirmed the possibility of acquired resistance to immune checkpoint inhibitors (ICIs) which can lead to late relapses. Chemotherapy can act as a priming therapy to increase a tumor's response to immunotherapy. We aim through this review to explain the mechanism behind ICI resistance and the value of chemotherapy in escaping this resistance. Finally, all US FDA approvals regarding the management of metastatic non-small-cell lung cancer using a combination of ICIs and chemotherapy are summarized.

KW - chemotherapy

KW - combination therapy

KW - hyperprogressive disease

KW - immune checkpoint inhibitors

KW - immunotherapy

KW - microenvironment

KW - NSCLC

KW - tumor inflammation

UR - http://www.scopus.com/inward/record.url?scp=85122737541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122737541&partnerID=8YFLogxK

U2 - 10.2217/imt-2021-0014

DO - 10.2217/imt-2021-0014

M3 - Review article

C2 - 34865502

AN - SCOPUS:85122737541

SN - 1750-743X

VL - 14

SP - 155

EP - 167

JO - Immunotherapy

JF - Immunotherapy

IS - 2

ER -

The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this